Insmed Reports Third-Quarter Results, Raises 2026 Sales Guidance
Insmed reported a narrower year-over-year net loss and raised its 2026 sales outlook to $1.81 billion-$1.87 billion. Its ARIKAYCE revenue outlook is now $460 million-$470 million.
Insmed Incorporated reported its financial results for the third quarter of 2026, highlighting a narrowing of its net loss compared to the same period in the prior year. Alongside the financial results, the company updated its full-year 2026 guidance, including an increase in the revenue outlook for its ARIKAYCE treatment to a range of $460 million to $470 million. The company also raised its overall fiscal year 2026 sales guidance to a range of $1.81 billion to $1.87 billion. These updates reflect the company's ongoing commercial performance and strategic focus on its rare disease portfolio.